多西他赛联合顺铂治疗铂敏感型复发性卵巢癌的效果、安全性研究

Study on the Efficacy and Safety of Docetaxel Combined with Cisplatin in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer

目的:研究多西他赛联合顺铂治疗铂敏感型复发性(PSR)卵巢癌的效果及安全性。方法:将某院2018年1月~2020年6月期间收治的140例PSR卵巢癌患者随机分为C组和S+D组各70例,C组采用紫杉醇联合顺铂治疗,S+D组采用多西他赛联合顺铂治疗。对比两组患者的肿瘤干预客观效果及化疗毒副反应发生率。结果:S+D组患者肿瘤干预稳定率为78.57%,高于C组的58.57%(P<0.05);S+D组患者肿瘤干预改善率为50.00%,高于C组的30.00%(P<0.05)。S+D组患者脱发、胃肠道反应、神经毒性、白细胞减少、血小板减少、肝肾功能下降毒副反应的发生率与C组比较无明显差异(P>0.05)。结论:多西他赛联合顺铂治疗PSR卵巢癌的临床疗效良好,且具有较高的安全性。

Objective:To investigate the efficacy and safety of docetaxel combined with cisplatin in the treatment of platinum-sensitive recurrent(PSR)ovarian cancer.Methods:140 cases of PSR ovarian cancer patients admitted to a hospital from January 2018 to June 2020 were randomly divided into group C(n=70)and group S+D(n=70).Group C was treated with paclitaxel+cisplatin,and group S+D was treated with docetaxel+cisplatin.The objective effect of tumor intervention and the incidence of toxic and side reactions of chemotherapy were compared between the two groups.Results:The tumor intervention stability rate of group S+D was 78.57%,which was higher than that of group C(58.57%,P<0.05).The improvement rate of tumor intervention in group S+D was 50.00%,which was higher than 30.00%in group C(P<0.05).There was no significant difference in the incidence of adverse reactions of alopecia,gastrointestinal reactions,neurotoxicity,leucopenia,thrombocytopenia,liver and kidney function decline between the two groups(P>0.05).Conclusion:Docetaxel combined with cisplatin has good clinical efficacy and safety in the treatment of PSR ovarian cancer.